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Introduction

Methods (Cont.)

The prevalence of Vitamin B12 deficiency is
between 8 and 16% in adults between the ages of
24 and 64 years and higher in the elderly.2 The
serious clinical sequalae of long-term vitamin B
deficiency, include neurocognitive changes,3
paresthesia, numbness and gait problems.4 If the
deficiency continues for an extended period of
time, these changes can be permanent and
debilitating.5 Given these serious consequences, it
is essential that practitioners effectively treat
patients with this deficiency.

Patients were exclude from this study if they were
vomiting and/or had diarrhea, alcohol use greater
than 40 g/d, inability to provide informed consent,
history of malignancy, folate deficiency, inability to
ingest oral medication, pregnant or breastfeeding,
and using a medication that would interfere with
folate metabolism such as methotrexate or
colchicine. The patients were assigned using
block randomized study to be a part of the PO
group or IM group receiving 1000-µg cobalamin
once daily for the first ten days, followed by once
weekly for four weeks, and then once monthly for
life. To ensure the success of the treatment the
patients were assessed for reticulocytosis until it
was detected between days five and ten of
treatment. In order to determine therapeutic
effectiveness, on days 0, 10, 30, and 90
hematologic parameters were measured as well
as serum vitamin B12 concentrations on days 0
and 90. Laboratory tests of serum potassium
levels and eosinophilia blood smears as well as
patient interviews were conducted by
Hematologists on days 0, 30, and 90 to determine
tolerability of both treatment options. The authors
compared the cost of the study drug and of the
injections. Wilcoxon and Mann-Whitney U
statistical analysis tests were used to compare
the oral and parenteral treatment arms. 2-paired t
test were used to compare pretreatment and
posttreatment values. Lastly, the nominal
variables were compared using the Yates chisquare test and the p values were considered to
be statistically significant at <0.05. Funding
source not stated in article.

The standard of care for vitamin B12 deficiency is
to provide monthly intramuscular injections of
cobolamin.6 However, this method has several
drawbacks, including requiring clinic
appointments, travel by the patient, time
commitments, and associated expenses. An
alternative treatment that allowed home care
could provide the dual benefits of improved costeffectiveness and greater convenience.
In this single-center, prospective, randomized,
open-labeled study, the cheapest and most
effective treatment for megaloblastic anemia
resulting from a cobalamin deficiency was
investigated. This article compared the use of
intramuscular injections to the oral administration
of cyanocobalamin in 70 patients over 90 days,
comparing both effectiveness and cost. From this
the authors concluded that oral cobalamin
treatment was equally effective at treating vitamin
B12 deficiency as intramuscular injections. They
also concluded that oral therapy was less
expensive and better tolerated.

Purpose
The purpose of this study was to compare the
treatments of PO versus IM cobalamin for
patients with megaloblastic anemia due to a
cobalamin deficiency in terms of cost and
effectiveness.

Treatment 1000µg of cobalamin

First 10 days
• Once Daily

• PO Group
• IM Group
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PO Group
• n = 26
• Age
• Mean: 60
• Range: 32-84
• Sex
• Men: 16
• Women: 10

IM Group
• n = 34
• Age
• Mean: 64
• Range: 36-87
• Sex
• Men: 17
• Women: 17

Results

Conclusions
From these results it can be concluded that PO
cobalamin treatment is as effective as IM
cobalamin treatment when treating patients with
metaplastic anemia due to a cobalamin
deficiency. It was also determined that the PO
treatment was more tolerated and less expensive
in comparison to the IM treatment costing $80
oppose $220, respectively. Within this study there
were many strengths including that it was done
simply to investigate the possibility of
administering B12 orally, the authors, as a result,
present as being unbiased. Another strength of
this article was its design employed block
randomization and had statistically similar control
and test groups, making the outcomes, as far as
statistically possible, reliable. The study also had
many weaknesses including is limited sample size
(60 people) with 30 or fewer in the control and
treatment groups. Additionally, due to lack of
available standardized dosage forms, liquid
vitamin B12 was mixed with fruit juice to
administer the PO dosage, which may have
skewed the results of this study. Future studies
should be performed and focus on using
commercially available preparations of B12 that
can be standardized and easily administered in a
multi-center clinical trial. Also, the number of
patients enrolled needs to be much larger than
any of the previous studies have been able to
muster.
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After 4 weeks for
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After 10 days to
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